Innovent Biologics, Inc.
HKEX:1801.HK
35.05 (HKD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Innovent Biologics, Inc. |
Symbool | 1801.HK |
Munteenheid | HKD |
Prijs | 35.05 |
Beurswaarde | 57,328,831,500 |
Dividendpercentage | 0% |
52-weken bereik | 28.3 - 52.15 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. De-Chao Yu Ph.D. |
Website | https://www.innoventbio.com |
An error occurred while fetching data.
Over Innovent Biologics, Inc.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (HKD)
Cijfers zijn in miljoenen (HKD)